阿魏酸哌嗪联合厄贝沙坦治疗慢性肾衰疗效及安全性分析

Analysis of curative effects and safety of piperazine ferulate combined with irbesartan in treatment of chronic renal failure

目的探讨阿魏酸哌嗪联合厄贝沙坦治疗慢性肾衰的临床疗效及安全性。方法选择医院收治的慢性肾衰患者62例作为研究对象,随机分为观察组及对照组各31例,对照组在常规治疗基础上给予阿魏酸哌嗪治疗,观察组在对照组基础上加用厄贝沙坦,治疗时间2个月。对两组临床疗效、治疗前后肾功能指标、不良反应发生情况以及生活质量进行观察与比较。结果观察组治疗后显效率、总有效率均高于对照组(P<0.05)。两组治疗后血肌酐(Cr)、血尿素氮(BUN)及尿蛋白(PRO)显著下降,内生肌酐清除率(Ccr)显著升高,而观察组Cr、BUN及PRO显著低于对照组,Ccr显著高于对照组(P<0.05)。两组不良反应发生率无统计学差异(P>0.05)。观察组在生理功能(PF)、生理职能(RP)、躯体疼痛(BP)、总体健康(GH)、活力(VT)得分均显著高于对照组(P<0.05)。结论阿魏酸哌嗪联合厄贝沙坦治疗慢性肾衰具有良好的临床疗效及安全性,对于患者生活质量改善具有积极的意义,值得推广应用。

Objective To explore the clinical effects and safety of piperazine ferulate combined with irbesartan in treatment of chronic renal failure. Methods A total of 62 patients suffering chronic renal failure to receive treatment in our hospital were selected as research subjects and divided randomly into an observation group and a control group（n = 31, respectively）. The control group was administered with piperazine ferulate on the basis of conventional treatment, and the observation group was administered with irbesartan on the basis of the treatment in the control group. The treatment time period was two months. The clinical effects, renal function indicators before and after the treatment, the adverse reactions, and the quality of life were observed and compared between the two groups. Results After the treatment, the curative effects and total effective rate in the observation group were higher than those in the control group（P 〈0.05）; the serum creatinine（Cr）, blood urea nitrogen（BUN） and urinary protein（PRO） in both groups decreased significantly, and creatinine clearance rate（Ccr） increased significantly; the Cr, BUN and PRO in the observation group were significantly lower than those in the control group, while the Ccr was significantly higher than that in the control group（P〈0.05）.There was no significant difference in adverse reaction between the two groups（P〈0.05）. The physiological function（PF）, role physical（RP）, body pain（BP）, general health（GH）, and vitality（VT） scores in the observation group were significantly higher than those in the control group（P〈0.05）. Conclusion Piperazine ferulate combined with irbesartan in the treatment of chronic renal failure has good clinical effects and high safety, and has positive significance in the improvement of the life quality of the patients; it is worthy of popularization and application.